One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Computer-aided Drug Discovery Market

コンピューター支援創薬市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] Computer-aided Drug Discovery Market by Type (Structure-based Drug Design (SBDD), Ligand-based Drug Design (LBDD), Sequence-based Approaches), Therapeutic Area (Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, and Others), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028


Product Code : RDHC00115196
Survey : Research Dive
Publish On : September, 2021
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5700 / Question Form
5 User USD8700 / Question Form
Enterprise User USD10700 / Question Form
BOCSCI Inc., Bioduro-Sundia, Schrödinger, Inc., Aragen Life Sciences Pvt. Ltd., Aris Pharmaceuticals, Inc, Charles River Laboratories, Bayer AG, AstraZeneca, and Albany Molecular Research Inc. (AMRI).

[Report Description]

According to Research Dive analysis, the global computer-aided drug discovery market is estimated to generate a revenue of $7,915.9 million by 2028, increasing from $2,746.9 million in 2020, at a healthy CAGR of 15.0%.

Impact Analysis of COVID-19 on the Global Computer-aided Drug Discovery Market:
The global computer aided drug discovery market experienced a higher growth rate during the Covid-19 pandemic. Due to increasing number of infection cases, worldwide, lack of a proper potent drug for the treatment and quick mutation in the viral genome, the computer aided drug discovery market has observed an exponential growth. The coronavirus pandemic has pressurized the researchers and scientists, from across the world to initiate their research for studying the viral genome in detail and develop a potent drug using computational software. Also, some major market players have come forward and collaborated together to work on COVID-19 drug development using computer aided drug discovery. Such factors are attributed to the growth of the market in the coming years.

Computer-aided Drug Discovery Market Analysis:
The computer aided drug discovery market experienced appreciable growth due to increasing cases of chronic diseases. Continuous rising number of unknown diseases has boosted the research activities and experiments. Computer aided drug discovery helps in studying the interaction between the target biological molecule and its corresponding ligand. It also helps in drug development, is a cost effective approach and takes approximately less time compared to wet laboratory experiments. Such factors are expected to drive the market of computer aided drug discovery in the forecast timeframe. Furthermore, increasing integration of artificial intelligence with computer aided drug discovery is anticipated to raise the market share in the global computer aided drug discovery market.
However, lack of skilled professionals to operate and handle software for computer aided drug discovery is expected to restrain the market growth. The computer aided drug discovery tools require a complete database of 3 D structure of proteins and other biomolecules. In case of unknown disease or less studied disease, the tools are unable to provide any good result. This factor is also likely to hamper the market growth.
Major technological advancements in computer aided drug discovery is expected to open various opportunities for the market in the future. The use of computer-aided drug discovery (CADD), is widely used by drug discovery companies to develop drugs against the diseases in a cost effective and rapid way. This software technology is now-a-days integrated with emerging technologies such as machine learning (ML) and artificial intelligence (AI) which drive the research programs in the biotechnological and pharmaceutical industries. Many companies have got a tremendous opportunity to mark their presence in the global market by opting for collaborations and partnerships with key players working in the artificial intelligence and computer aided drug discovery field.
Based on type, the global computer aided drug discovery market is divided into structure based drug design, ligand-based drug design and sequence-based approaches.
The structure based drug design sub-segment shall have the fastest market growth and it is anticipated to generate a revenue of $ 2,539.4 million by 2028.
Based on therapeutic area, the market is classified into the oncology, neurology, cardiovascular disease, respiratory disease, diabetes, and others. The oncology sub-segment garnered $ 636.6 million in 2020 and is projected to grow exponentially by 2028.
Based on the end users, the market is segmented into the pharmaceutical companies, biotechnology companies, and research laboratories. The research laboratories sub-segment is predicted to be growing significantly and it is expected to cross $ 3,269.7 million by 2028.
Based on geographical scope, the market was investigated across North America, Europe, Asia-Pacific, and LAMEA. The Asia-Pacific application computer aided drug discovery market is anticipated to rise at a growth rate of 16.4% by 2028 from the revenue generated in 2020.
The companies involved in the global computer-aided drug discovery market are BOCSCI Inc., Bioduro-Sundia, Schrödinger, Inc., Aragen Life Sciences Pvt. Ltd., Aris Pharmaceuticals, Inc, Charles River Laboratories, Bayer AG, AstraZeneca, and Albany Molecular Research Inc. (AMRI).

CHAPTER 1:RESEARCH METHODOLOGY

1.1.Desk research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions & forecast parameters

1.4.1.Assumptions
1.4.2.Forecast parameters

CHAPTER 2:EXECUTIVE SUMMARY

2.1.360° summary
2.2.Type trends
2.3.Therapeutic Area trends
2.4.End-user trends

CHAPTER 3:MARKET OVERVIEW

3.1.Market segmentation & definitions
3.2.Key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.2.1.Top winning strategies, by year
3.2.2.2.Top winning strategies, by development
3.2.2.3.Top winning strategies, by company

3.3.Porter’s five forces analysis
3.4.Market dynamics
3.5.Drivers

3.5.1.Rising demand for development of new drugs to boost the market growth
3.5.2.Integration of artificial intelligence for drug discovery may create attractive opportunities for the key players

3.6.Restraints

3.6.1.Lack of skilled technicians for operating computer aided drug discovery software to restrain the market growth

3.7.Opportunities

3.7.1.Advancements in computer-aided drug discovery to create massive investment opportunities

3.8.Regulatory landscape
3.9.Patent landscape
3.10.Technological landscape
3.11.Market value chain analysis
3.12.Strategic Overview

CHAPTER 4:IMPACT OF COVID-19 ON COMPUTER-AIDED DRUG DISCOVERY MARKET

4.1.Introduction
4.2.COVID-19 health assessment
4.3.Impact of COVID-19 on the global economy
4.4.Impact of COVID-19 on global computer aided drug discovery market

4.4.1.Social impact
4.4.2.Technological impact
4.4.3.Investment scenario

4.5.Global Computer-Aided Drug Discovery market size and forecast, by region, 2019-2021

CHAPTER 5:GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE

5.1.Overview

5.1.1.Market size and forecast, by type

5.2.Structure-based Drug Design (SBDD)

5.2.1.Key market trends, growth factors and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market share analysis, by country

5.3.Ligand-based drug design (LBDD)

5.3.1.Key market trends, growth factors and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market share analysis, by country

5.4.Sequence-based approaches

5.4.1.Key market trends, growth factors and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market share analysis, by country

CHAPTER 6:GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA

6.1.Overview

6.1.1.Market size and forecast, by therapeutic area

6.2.Oncology

6.2.1.Key market trends, growth factors and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market share analysis, by country

6.3.Neurology

6.3.1.Key market trends, growth factors and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market share analysis, by country

6.4.Cardiovascular diseases

6.4.1.Key market trends, growth factors and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market share analysis, by country

6.5.Respiratory diseases

6.5.1.Key market trends, growth factors and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market share analysis, by country

6.6.Diabetes

6.6.1.Key market trends, growth factors and opportunities
6.6.2.Market size and forecast, by region
6.6.3.Market share analysis, by country

6.7.Others

6.7.1.Key market trends, growth factors and opportunities
6.7.2.Market size and forecast, by region
6.7.3.Market share analysis, by country

CHAPTER 7:GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END-USER

7.1.Overview

7.1.1.Market size and forecast, by end-user type

7.2.Pharmaceutical companies

7.2.1.Key market trends, growth factors and opportunities
7.2.2.Market size and forecast, by region
7.2.3.Market share analysis, by country

7.3.Biotechnology companies

7.3.1.Key market trends, growth factors and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market share analysis, by country

7.4.Research institutes

7.4.1.Key market trends, growth factors and opportunities
7.4.2.Market size and forecast, by region
7.4.3.Market share analysis, by country

CHAPTER 8:GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast, by region

8.2.North America

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.Market size and forecast, by type
8.2.3.Market size and forecast, by therapeutic area
8.2.4.Market size and forecast, by end-user
8.2.5.Market size and forecast, by country
8.2.6.U.S.

8.2.6.1.Market size and forecast, by type
8.2.6.2.Market size and forecast, by therapeutic area type
8.2.6.3.Market size and forecast, by end-user

8.2.7.Canada

8.2.7.1.Market size and forecast, by type
8.2.7.2.Market size and forecast, by therapeutic area type
8.2.7.3.Market size and forecast, by end-user

8.2.8.Mexico

8.2.8.1.Market size and forecast, by type
8.2.8.2.Market size and forecast, by therapeutic area type
8.2.8.3.Market size and forecast, by end-user

8.3.Europe

8.3.1.Key market trends, growth factors, and opportunities
8.3.2.Market size and forecast, by type
8.3.3.Market size and forecast, by therapeutic area type
8.3.4.Market size and forecast, by end-user
8.3.5.Market size and forecast, by country
8.3.6.Germany

8.3.6.1.Market size and forecast, by type

8.3.6.2.Market size and forecast, by therapeutic area type
8.3.6.3.Market size and forecast, by end-user

8.3.7.UK

8.3.7.1.Market size and forecast, by type
8.3.7.2.Market size and forecast, by therapeutic area type
8.3.7.3.Market size and forecast, by end-user

8.3.8.France

8.3.8.1.Market size and forecast, by type
8.3.8.2.Market size and forecast, by therapeutic area type
8.3.8.3.Market size and forecast, by end-user

8.3.9.Spain

8.3.9.1.Market size and forecast, by type
8.3.9.2.Market size and forecast, by therapeutic area type
8.3.9.3.Market size and forecast, by end-user

8.3.10.Italy

8.3.10.1.Market size and forecast, by type
8.3.10.2.Market size and forecast, by therapeutic area type
8.3.10.3.Market size and forecast, by end-user

8.3.11.Rest of Europe

8.3.11.1.Market size and forecast, by type
8.3.11.2.Market size and forecast, by therapeutic area type
8.3.11.3.Market size and forecast, by end-user

8.4.Asia-Pacific

8.4.1.Key market trends, growth factors, and opportunities
8.4.2.Market size and forecast, by type
8.4.3.Market size and forecast, by therapeutic area type
8.4.4.Market size and forecast, by end-user
8.4.5.Market size and forecast, by country
8.4.6.China

8.4.6.1.Market size and forecast, by type
8.4.6.2.Market size and forecast, by therapeutic area type
8.4.6.3.Market size and forecast, by end-user

8.4.7.Japan

8.4.7.1.Market size and forecast, by type
8.4.7.2.Market size and forecast, by therapeutic area type
8.4.7.3.Market size and forecast, by end-user

8.4.8.India

8.4.8.1.Market size and forecast, by type
8.4.8.2.Market size and forecast, by therapeutic area type
8.4.8.3.Market size and forecast, by end-user

8.4.9.South Korea

8.4.9.1.Market size and forecast, by type
8.4.9.2.Market size and forecast, by therapeutic area type
8.4.9.3.Market size and forecast, by end-user

8.4.10.Australia

8.4.10.1.Market size and forecast, by type
8.4.10.2.Market size and forecast, by therapeutic area type
8.4.10.3.Market size and forecast, by end-user

8.4.11.Rest of Asia-Pacific

8.4.11.1.Market size and forecast, by type
8.4.11.2.Market size and forecast, by therapeutic area type
8.4.11.3.Market size and forecast, by end-user

8.5.LAMEA

8.5.1.Key market trends, growth factors, and opportunities
8.5.2.Market size and forecast, by type
8.5.3.Market size and forecast, by therapeutic area type
8.5.4.Market size and forecast, by end-user
8.5.5.Market size and forecast, by country
8.5.6.Latin America

8.5.6.1.Market size and forecast, by type
8.5.6.2.Market size and forecast, by therapeutic area type
8.5.6.3.Market size and forecast, by end-user

8.5.7.Middle East

8.5.7.1.Market size and forecast, by type
8.5.7.2.Market size and forecast, by therapeutic area type
8.5.7.3.Market size and forecast, by end-user

8.5.8.Africa

8.5.8.1.Market size and forecast, by type
8.5.8.2.Market size and forecast, by therapeutic area type
8.5.8.3.Market size and forecast, by end-user

CHAPTER 9:GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, COMPANY PROFILES

9.1.BOCSCI INC.

9.1.1.Company overview
9.1.2.Product portfolio
9.1.3.Key strategy moves and developments

9.2.BIODURO-SUNDIA

9.2.1.Company overview
9.2.2.Product portfolio
9.2.3.Key strategy moves and developments

9.3.SCHRÖDINGER, INC.

9.3.1.Company overview
9.3.2.Operating business segments
9.3.3.Product portfolio
9.3.4.Business performance
9.3.5.Key strategy moves and developments

9.4.ARAGEN LIFE SCIENCES PVT. LTD.

9.4.1.Company overview
9.4.2.Product portfolio

9.5.ARIS PHARMACEUTICALS, INC.

9.5.1.Company overview
9.5.2.Product portfolio

9.6.CHARLES RIVER LABORATORIES.

9.6.1.Company overview
9.6.2.Operating business segments
9.6.3.Product portfolio
9.6.4.Business performance
9.6.5.Key strategy moves and developments

9.7.BAYER AG

9.7.1.Company overview
9.7.2.Product portfolio
9.7.3.Operating business segments
9.7.4.Business performance
9.7.5.Key strategy moves and developments

9.8.ASTRAZENECA

9.8.1.Company overview
9.8.2.Business performance
9.8.3.Key strategic moves and developments

9.9.ALBANY MOLECULAR RESEARCH INC. (AMRI)

9.9.1.Company overview
9.9.2.Product portfolio
9.9.3.Key strategic moves and developments

9.10.EVOTEC SE

9.10.1.Company overview
9.10.2.Product portfolio
9.10.3.Operating business segments
9.10.4.Business performance
9.10.5.Key strategic moves and developments

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+